Insmed (INSM) Gross Profit Growth (3y) (2021 - 2026)
Insmed (INSM) Gross Profit Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 9.20% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.09% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 77.42% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 28.75% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.27% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 59.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -45.72% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 80.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.79% |
| Mar 31, 2026 | 71.36% |
| Dec 31, 2025 | 68.11% |
| Sep 30, 2025 | 27.69% |
| Jun 30, 2025 | 17.57% |
| Mar 31, 2025 | 20.47% |
| Dec 31, 2024 | 22.26% |
| Sep 30, 2024 | 25.48% |
| Jun 30, 2024 | 26.19% |
| Mar 31, 2024 | 24.10% |
| Dec 31, 2023 | 28.78% |
| Sep 30, 2023 | 23.61% |
| Jun 30, 2023 | 23.05% |
| Mar 31, 2023 | 21.82% |
| Dec 31, 2022 | 7.71% |
| Sep 30, 2022 | 18.69% |
| Jun 30, 2022 | 24.91% |
| Mar 31, 2022 | 32.09% |
| Dec 31, 2021 | 79.46% |